May 14, 2009 - The FDA has cleared PhotoDetection Systems’ (PDS) NeuroPET scanner, a system designed to serve the clinical and research needs of the molecular neuro-imaging community.

NeuroPET’s patented wavelength-shifting fiber technology enables ultra high-sensitivity and excellent spatial resolution. Its compact/portable design requires no special site preparation and allows for significantly reduced cost of ownership compared to general-purpose PET scanners. NeuroPET uses very low doses of 18F and 11C tracers to image metabolism, amyloid, and dopaminergic binding in neurological diseases. These tracers are known to be helpful in imaging challenging and costly diseases such as Alzheimer’s, Parkinson’s, neuro-oncology, and neuro-psychiatric disorders.

NeuroPET can complement existing clinical and research efforts with high quality, low cost neuro-imaging capacity and its ultra high-sensitivity performance can allow for more frequent repeat low dose scanning of the same subject to monitor response to therapy.

For more information: www.photodetection.com


Related Content

News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
Subscribe Now